GlassScriptPhysician profile
Andrea Rae Mitchell
NPI 1346948551
$6,142.97
in general payments reported to CMS, 2019-2025
21 companies · $3,509 in 2025
The $3,509 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $867 · 2024: $1,767 · 2025: $3,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,104 · Education: $38.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,103.98 |
| Education | $38.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,001.68 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $917.85 | 2023-2025 | Auvelity |
| Abbvie INC. | $885.03 | 2023-2025 | |
| Lundbeck LLC | $665.91 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $446.84 | 2025 | Fanapt |
| Corium, LLC | $403.82 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $277.97 | 2023-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $238.31 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $237.99 | 2023-2025 | Ingrezza |
| Almatica Pharma LLC | $179.42 | 2024-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $170.28 | 2023-2024 | Trintellix |
| Tris Pharma INC | $130.58 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $110.39 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $98.27 | 2023-2025 | Austedo Xr, Austedo Xr |
| Sage Therapeutics, LLC | $72.65 | 2024-2025 | Zurzuvae |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $66.01 | 2025 | Cobenfy |
| Bausch Health US, LLC | $64.57 | 2023 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $62.96 | 2023-2025 | Quviviq, Quviviq |
| Alkermes, INC. | $52.18 | 2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $46.01 | 2025 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $14.25 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.